vs
Mediaco Holding Inc.（MDIA）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Mediaco Holding Inc.的季度营收约是REGENXBIO Inc.的1.3倍（$38.7M vs $30.3M），Mediaco Holding Inc.净利率更高（-83.6% vs -221.3%，领先137.7%），REGENXBIO Inc.同比增速更快（43.0% vs 17.9%），Mediaco Holding Inc.自由现金流更多（$-460.0K vs $-52.8M），过去两年Mediaco Holding Inc.的营收复合增速更高（140.1% vs 39.4%）
MediaCo控股公司是一家美国传媒企业，总部设于加利福尼亚州伯班克与纽约市，由私募股权公司HPS投资合伙公司与Standard General控股。该集团主要服务非裔美国及西班牙语裔社群，在多个顶级多元文化市场拥有电视台和广播电台，是Estrella TV电视网的母公司。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
MDIA vs RGNX — 直观对比
营收规模更大
MDIA
是对方的1.3倍
$30.3M
营收增速更快
RGNX
高出25.1%
17.9%
净利率更高
MDIA
高出137.7%
-221.3%
自由现金流更多
MDIA
多$52.3M
$-52.8M
两年增速更快
MDIA
近两年复合增速
39.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $38.7M | $30.3M |
| 净利润 | $-32.3M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -16.0% | -190.0% |
| 净利率 | -83.6% | -221.3% |
| 营收同比 | 17.9% | 43.0% |
| 净利润同比 | -661.9% | -31.2% |
| 每股收益（稀释后） | $-0.39 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MDIARGNX
| Q4 25 | $38.7M | $30.3M | ||
| Q3 25 | $35.4M | $29.7M | ||
| Q2 25 | $31.2M | $21.4M | ||
| Q1 25 | $28.0M | $89.0M | ||
| Q4 24 | $32.8M | $21.2M | ||
| Q3 24 | $29.9M | $24.2M | ||
| Q2 24 | $26.2M | $22.3M | ||
| Q1 24 | $6.7M | $15.6M |
净利润MDIARGNX
| Q4 25 | $-32.3M | $-67.1M | ||
| Q3 25 | $-17.9M | $-61.9M | ||
| Q2 25 | $-7.4M | $-70.9M | ||
| Q1 25 | $-8.6M | $6.1M | ||
| Q4 24 | $-4.2M | $-51.2M | ||
| Q3 24 | $54.9M | $-59.6M | ||
| Q2 24 | $-48.3M | $-53.0M | ||
| Q1 24 | $-3.7M | $-63.3M |
毛利率MDIARGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率MDIARGNX
| Q4 25 | -16.0% | -190.0% | ||
| Q3 25 | -20.0% | -176.3% | ||
| Q2 25 | -21.7% | -296.3% | ||
| Q1 25 | -16.7% | 13.6% | ||
| Q4 24 | -13.8% | -242.1% | ||
| Q3 24 | -23.0% | -256.6% | ||
| Q2 24 | -50.9% | -251.3% | ||
| Q1 24 | -51.7% | -408.8% |
净利率MDIARGNX
| Q4 25 | -83.6% | -221.3% | ||
| Q3 25 | -50.5% | -208.3% | ||
| Q2 25 | -23.7% | -331.8% | ||
| Q1 25 | -30.7% | 6.8% | ||
| Q4 24 | -12.9% | -241.3% | ||
| Q3 24 | 184.0% | -246.3% | ||
| Q2 24 | -184.4% | -237.7% | ||
| Q1 24 | -54.8% | -405.4% |
每股收益（稀释后）MDIARGNX
| Q4 25 | $-0.39 | $-1.30 | ||
| Q3 25 | $-0.22 | $-1.20 | ||
| Q2 25 | $-0.11 | $-1.38 | ||
| Q1 25 | $-0.12 | $0.12 | ||
| Q4 24 | $0.19 | $-0.99 | ||
| Q3 24 | $0.66 | $-1.17 | ||
| Q2 24 | $-0.75 | $-1.05 | ||
| Q1 24 | $-0.18 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.1M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $46.3M | $102.7M |
| 总资产 | $291.1M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MDIARGNX
| Q4 25 | $5.1M | $230.1M | ||
| Q3 25 | $6.2M | $274.2M | ||
| Q2 25 | $2.9M | $323.3M | ||
| Q1 25 | $6.3M | $267.9M | ||
| Q4 24 | $4.4M | $234.7M | ||
| Q3 24 | $7.7M | $255.5M | ||
| Q2 24 | $9.9M | $290.4M | ||
| Q1 24 | $4.0M | $338.7M |
股东权益MDIARGNX
| Q4 25 | $46.3M | $102.7M | ||
| Q3 25 | $86.7M | $161.5M | ||
| Q2 25 | $97.3M | $213.7M | ||
| Q1 25 | $85.5M | $274.2M | ||
| Q4 24 | $62.1M | $259.7M | ||
| Q3 24 | $67.9M | $301.4M | ||
| Q2 24 | $13.7M | $348.3M | ||
| Q1 24 | $33.3M | $390.7M |
总资产MDIARGNX
| Q4 25 | $291.1M | $453.0M | ||
| Q3 25 | $319.4M | $525.2M | ||
| Q2 25 | $315.1M | $581.0M | ||
| Q1 25 | $317.7M | $490.9M | ||
| Q4 24 | $325.5M | $466.0M | ||
| Q3 24 | $338.4M | $519.1M | ||
| Q2 24 | $338.6M | $569.4M | ||
| Q1 24 | $325.5M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.0K | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-460.0K | $-52.8M |
| 自由现金流率自由现金流/营收 | -1.2% | -174.0% |
| 资本支出强度资本支出/营收 | 1.3% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $1.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流MDIARGNX
| Q4 25 | $32.0K | $-52.3M | ||
| Q3 25 | $2.8M | $-56.0M | ||
| Q2 25 | $-3.0M | $-49.3M | ||
| Q1 25 | $2.1M | $33.6M | ||
| Q4 24 | $10.9M | $-31.6M | ||
| Q3 24 | $-6.0M | $-40.5M | ||
| Q2 24 | $-25.1M | $-45.5M | ||
| Q1 24 | $412.0K | $-55.5M |
自由现金流MDIARGNX
| Q4 25 | $-460.0K | $-52.8M | ||
| Q3 25 | $2.8M | $-56.5M | ||
| Q2 25 | $-3.2M | $-49.7M | ||
| Q1 25 | $2.0M | $32.6M | ||
| Q4 24 | $10.5M | $-32.7M | ||
| Q3 24 | $-6.6M | $-40.9M | ||
| Q2 24 | $-25.2M | $-46.0M | ||
| Q1 24 | $386.0K | $-56.0M |
自由现金流率MDIARGNX
| Q4 25 | -1.2% | -174.0% | ||
| Q3 25 | 8.0% | -189.9% | ||
| Q2 25 | -10.2% | -232.8% | ||
| Q1 25 | 7.1% | 36.6% | ||
| Q4 24 | 31.9% | -154.2% | ||
| Q3 24 | -22.2% | -168.9% | ||
| Q2 24 | -96.1% | -206.2% | ||
| Q1 24 | 5.8% | -358.5% |
资本支出强度MDIARGNX
| Q4 25 | 1.3% | 1.7% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.7% | 1.8% | ||
| Q1 25 | 0.2% | 1.2% | ||
| Q4 24 | 1.2% | 5.1% | ||
| Q3 24 | 2.1% | 1.3% | ||
| Q2 24 | 0.3% | 2.1% | ||
| Q1 24 | 0.4% | 3.6% |
现金转化率MDIARGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.11× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MDIA
| Video Segment | $26.4M | 68% |
| Advertising | $10.0M | 26% |
| Other | $1.7M | 4% |
| Service Other | $536.0K | 1% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
